Drugs / Lorcaserin
Lorcaserin
also known as
APD356 · Lorcaserin Hydrochloride · Belviq · ADP-356 · Belviq XR · lorcaserin extended-release · Lorcaserin HCl · lorcaserin hydrochloride XR · +3 more
Small molecule targets HTR2C via activation
Trials 39 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT04205071 | Nov 2020 → Dec 2021 | chemotherapy-induced neuropathy, digestive system carcinoma, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT03143855 | Jan 2017 → Apr 2019 | opiate dependence, opioid abuse | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1 | NCT02932215 | Oct 2016 → Jan 2019 | cannabis dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT03143543 | Jul 2015 → Dec 2019 | cocaine dependence, opiate dependence | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 1 | NCT02537873 | Jul 2015 → Jul 2018 | substance-related disorder | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1 | NCT02393599 | May → Aug 2015 | cocaine abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT02398669 | Mar → Apr 2015 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02192515 | Jul 2014 → Nov 2015 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02022956 | Dec 2013 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00828659 | Dec 2008 → Apr 2009 | substance abuse | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00829140 | Nov 2008 → Sep 2009 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00828724 | Nov → Dec 2008 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00828438 | Oct 2008 → Feb 2009 | impaired renal function disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00828581 | Oct → Dec 2008 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00828932 | Aug → Dec 2008 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03253926 | Sep 2017 → May 2021 | cannabis dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02523690 | Dec 2015 → Dec 2017 | infectious disease with sepsis, myopathy | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1/2 | NCT02680288 | Nov 2015 → Sep 2018 | substance-related disorder | Midwest Biomedical Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02393547 | Sep 2013 → Dec 2015 | nicotine dependence | Mayo Clinic | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04396834 | Dec 2019 → Feb 2020 | nicotine dependence | The Mind Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT04396847 | Oct 2019 → Feb 2020 | alcohol-related disorders, nicotine dependence | The Mind Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT03812523 | Jun 2019 → Feb 2021 | chemotherapy-induced neuropathy | Southeastern Regional Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02906644 | Nov 2016 → Mar 2018 | nicotine dependence | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT02044874 | Mar → Nov 2014 | — | Arena Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00116740 | Jun → Nov 2005 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00104507 | Dec 2004 → May 2005 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03169816 | May 2017 → Aug 2019 | substance-related disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT02412631 | Jun 2016 → Apr 2020 | obesity disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04572243 | Sep 2020 → Aug 2024 | myoclonic epilepsy | Eisai Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03720574 | Sep 2019 → Dec 2020 | obesity disorder | Kanion & Huawe Medicine Co.,Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT00603902 | Jan 2008 → Jul 2009 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00603291 | Dec 2007 → Jun 2010 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00395135 | Nov 2006 → Feb 2009 | obesity disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT03799198 | Jan 2019 → May 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT03338296 | Sep 2017 → Apr 2020 | obesity disorder | Eisai Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT02019264 | Jan 2014 → May 2018 | cardiovascular disorder, obesity disorder, type 2 diabetes mellitus | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01962402 | Jan 2014 → Jul 2015 | — | Southern California Institute for Research and Education | Unknown | No outcome recorded |
| Phase 4 | NCT01987427 | Oct 2013 → Aug 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04457687 | — | myoclonic epilepsy | Eisai Inc. | Available | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03637842 Comparator | Aug 2019 → Feb 2020 | cannabis dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03266939 Comparator | Oct 2018 | cocaine dependence | Mclean Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT03011645 Comparator | May 2018 → Jan 2020 | cardiovascular disorder | Duke University | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03192995 Comparator | Jan 2018 → Feb 2020 | substance-related disorder | Glenn-Milo Santos | Terminated | No outcome recorded |
| Phase 2 | NCT03007394 Comparator | Dec 2017 → Dec 2019 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02129608 Comparator | Jun 2014 → Dec 2015 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02796144 Comparator | Sep 2016 → Feb 2020 | obesity disorder, schizoaffective disorder, schizophrenia | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 4 | NCT02400359 Comparator | Oct 2014 → Jun 2027 expected | obesity disorder | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02388568 Comparator | Jan 2015 → Jun 2017 | obesity disorder | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lorcaserin | “Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.” PMID 19057523 ↗ Dec 200846“Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.)” NCT03799198 ↗ “A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects” NCT02192515 ↗ |
| Known as | ADP-356 | ChEMBL registry synonym — accepted as the source's own label CHEMBL360328 ↗ |
| Known as | APD356 | “APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks” NCT02044874 ↗ |
| Known as | Belviq | “Lorcaserin is a serotonin (5-HT) 2C receptor agonist (Trade Name Belviq) approved for treatment of obesity.” NCT03143855 ↗1“Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.)” NCT03799198 ↗ |
| Known as | Belviq XR | “Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.)” NCT03799198 ↗ |
| Known as | lorcaserin extended-release | “Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.)” NCT03799198 ↗ |
| Known as | Lorcaserin HCl | “A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes...” NCT02019264 ↗ |
| Known as | Lorcaserin Hydrochloride | “Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.” NCT03338296 ↗2“APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks” NCT02044874 ↗ “Drug: Lorcaserin Hydrochloride” NCT04205071 ↗ |
| Known as | lorcaserin hydrochloride XR | “Drug: lorcaserin hydrochloride XR” NCT03338296 ↗ |
| Known as | Lorcaserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL360328 ↗ |
| Known as | Lorcaserine | ChEMBL registry synonym — accepted as the source's own label CHEMBL360328 ↗ |
| Known as | Lorqess | ChEMBL registry synonym — accepted as the source's own label CHEMBL360328 ↗ |
| Action | Activate | “a novel, selective 5-HT2c receptor agonist” NCT00104507 ↗ |
| Modality | Small molecule | — CHEMBL360328 ↗ |
| Route | Oral | “single oral doses of lorcaserin (20, 40, and 60 mg), zolpidem (15 and 30 mg), ketamine (100 mg), and placebo was conducted” PMID 21412231 ↗ Mar 2011 |
| Target | HTR2C | “5HTR2C agonist (lorcaserin) to increase and antagonist (ziprasidone) to reduce cortisol response to mental and metabolic stress in men carrying the rs6318 C allele and women in...” NCT03011645 ↗ |